Group 1 - Guangdong Province has launched a training program for 1,000 "rural internet celebrities" to enhance their skills in account operation, live streaming, and short video creation [4][5][6] - The "Hundred Million Project" aims to develop two trillion-level industrial clusters, focusing on modern rural industry systems and the integration of primary, secondary, and tertiary industries [7][9][10] - The green low-carbon industry in Guangdong has reached a scale of 1.1 trillion yuan, playing a significant role in the province's high-quality development and supporting carbon neutrality goals [20][21][23][25] Group 2 - The "Sweet Connection" promotional event for Maoming longan and other local products was held in Shanghai to enhance agricultural cooperation between Guangdong and Shanghai [28][31] - The "Drought-resistant Rice" initiative in Huaiji County has achieved a yield of over 600 kg per mu, showcasing advancements in agricultural technology and practices [32][34] - The establishment of the first "Media+" alliance in Guangdong aims to support the "Hundred Million Project" and enhance the role of mainstream media in rural revitalization efforts [36][38][40]

在科技创新与学术交流深度交融的背景下，高峰论坛特邀中国科学院、中国工程院多位院士担任核心演讲嘉宾。此举旨在以前 沿科研洞见夯实论坛专业性，打通产学研转化路径，为战略产业升级注入科学动能。 两院院士作为中国科技界的领航者，其深度参与大幅提升论坛权威性： 二、学界影响力激活社会动能 院士参与带来的多维价值辐射： 三、战略合作机制的精细化运作 论坛主办方铭培网联合专业机构优化院士参与机制： 四、创新生态的长效价值 院士参与论坛持续释放创新红利： 院士群体的深度参与，使论坛成为国家创新体系的重要节点。随着科研端与产业端协作深化，这种"学术引擎+产业载体"模式将 持续释放创新裂变效应，为中国式现代化建设提供核心驱动力。 铭培网--作为全球高端专家资源平台，致力于汇聚国内外前政界人士、诺贝尔奖得主、经济学家、商业领袖、国学文化学者、军 事顾问及主持人等专业人才，通过组织论坛讲座、企业访问活动和管理咨询等，助力中国经济科技发展。邀请专家进行大会发 言、商务考察、或技术协作。 一、顶尖智脑锚定学术高度 1. 理论前沿性与实践融合：院士演讲内容涵盖基因编辑、人工智能、新材料等国家战略领域的最新突破，同步剖析技术落地 瓶颈与产业 ...

Core Viewpoint - The application of gene editing technology in agriculture is accelerating in China, with significant advancements in safety certifications and research outcomes, while also raising concerns about potential risks and societal acceptance [7][9][24]. Group 1: Gene Editing Developments - In April 2023, China issued its first biological safety certificate for agricultural gene-edited organisms, specifically for a high oleic acid soybean [8]. - By May 2024, the first safety certificate for a staple crop using gene editing is expected to be approved [9]. - Over the past decade, significant progress has been made in gene editing research for aquaculture, achieving important results across more than ten species [14]. Group 2: Benefits of Gene Editing - Gene editing technology can enhance the production performance and disease resistance of animals, as well as improve meat quality, showcasing immense potential in breeding [30]. - The combination of gene editing and selective breeding can significantly increase growth rates and feed conversion efficiency in agriculture [32]. - In aquaculture, gene editing allows for precise modifications of specific genes, addressing challenges such as low efficiency and limited breakthroughs in traditional breeding methods [34]. Group 3: Risks and Concerns - The scientific community is concerned about off-target effects, unpredictable genomic changes, and intergenerational inheritance issues related to gene editing [15][16]. - Specific risks in aquaculture include ecological escape and gene diffusion, which could impact wild populations and ecological balance [17][92]. - Potential risks from gene editing include the insertion of foreign DNA, new protein toxicity, and off-target mutations, which have not been fully assessed for safety [79][90]. Group 4: Safety Measures and Future Outlook - Scientists are exploring multi-layered control measures to balance technological benefits with safety, including rigorous screening and verification processes [102]. - The concept of "controlled sterility" is gaining traction, where gene-edited fish are rendered sterile to prevent environmental impact [114]. - Recent studies have shown that gene-edited fish do not exhibit significant differences in health compared to non-edited counterparts, providing a scientific basis for their application in aquaculture [130].

Core Viewpoint - The article discusses the significant impact of mosquitoes on global health, particularly in relation to malaria transmission and the innovative genetic research aimed at combating this issue through gene editing technology [2][3][4]. Group 1: Malaria and Mosquito Impact - In 2023, approximately 263 million people were infected with malaria, resulting in nearly 600,000 deaths, with 80% of these fatalities being children [2]. - Efforts to control malaria transmission have stagnated due to mosquitoes developing resistance to insecticides and the malaria-causing parasites becoming resistant to treatments like artemisinin [3]. Group 2: Genetic Research and Innovations - A study published in Nature by researchers from UC San Diego and Johns Hopkins University utilized CRISPR-Cas9 technology to edit the FREP1 gene in the major malaria vector, Anopheles stephensi, to block the transmission of malaria parasites [4][6]. - The specific genetic modification involved changing one amino acid from L224 to Q224 in the FREP1 gene, which effectively prevents malaria parasites from entering the mosquito's salivary glands without affecting the mosquito's normal growth and reproduction [6][8]. Group 3: Gene Drive System - The research team developed a linked allele drive system to ensure the rapid spread of the FREP1 Q224 allele within mosquito populations, achieving an increase from 25% to 93% frequency in just 10 generations [9]. - This innovative approach leverages a naturally occurring mosquito allele, providing a powerful barrier against multiple malaria parasites and potentially applicable to various mosquito species and populations [10].

Group 1: Cotton and Astaxanthin Production - Cotton is not only an important raw material for textiles but also has potential in producing valuable astaxanthin, a natural antioxidant [1] - The Chinese Academy of Agricultural Sciences has developed engineered cotton that can synthesize astaxanthin using plant synthetic biology techniques [1] - Astaxanthin has applications in food, feed, pharmaceuticals, and cosmetics, enhancing the value of cotton from a single output to multifunctional high-value products [1] Group 2: Citrus and Diabetes Treatment - Citrus peels are being explored for their added value, with recent research indicating that components extracted from citrus can significantly enhance wound healing for diabetes patients, improving healing speed by 2.7 times [2] - The development of a natural hydrogel with antibacterial and anti-inflammatory properties addresses slow healing in diabetic wounds [2] Group 3: Peach Sweetness and Softening Genes - Researchers have identified the genetic basis for the sweetness of peaches and the genes responsible for fruit softening during ripening [3] - The discovery of the "slow-softening peach" gene could lead to the development of varieties that are longer-lasting, flavorful, and better suited for transport [3] Group 4: Advances in Livestock Genetics - The first single-cell transcriptome atlas of water buffalo has been constructed, providing valuable resources for functional genomics and molecular breeding in agricultural animals [3] - A new 50K breeding chip for Chinese Yellow Cattle has been developed, offering low-cost and high-accuracy selection for efficient breeding and conservation of local cattle breeds [3] Group 5: Agricultural Biotechnology Innovations - Recent agricultural research achievements include the release of a comprehensive soybean protein quantitative atlas and the establishment of a genotype database for tea tree varieties [4] - The integration of cutting-edge biotechnology in agriculture is expected to drive modernization and innovation in the sector [4]

Core Viewpoint - The article highlights a groundbreaking achievement in neuroscience, specifically in gene editing for treating rare genetic disorders like Alternating Hemiplegia of Childhood (AHC), marking a significant milestone in personalized gene therapy [1][2]. Group 1: Research Breakthrough - Researchers successfully corrected gene mutations in the brain associated with AHC using a single injection technique, significantly improving symptoms and extending the lifespan of affected mice [1][2]. - The study, published in the journal Cell, involved a collaboration among institutions including the Jackson Laboratory and the Broad Institute, focusing on two common mutation sites in the ATP1A3 gene [2][3]. Group 2: Gene Editing Technology - The research tested next-generation gene editing technologies, with Prime Editing showing remarkable results by repairing up to 85% of mutated brain cells and restoring normal protein function [2][3]. - The use of a harmless virus, AAV9, as a delivery vehicle to cross the blood-brain barrier was a key innovation, allowing for effective gene editing in the brain [4][6]. Group 3: Implications for Treatment - This advancement opens new possibilities for treating not only AHC but also other hereditary neurological disorders, potentially transforming the approach to previously deemed "incurable" diseases [5][6]. - The combination of the viral delivery system and Prime Editing technology is seen as a revolutionary step in making precise brain gene editing a reality, with ongoing tests exploring the feasibility of intervention after symptoms appear [6].

Summary of the Conference Call Company and Industry Overview - The conference call involved Qiu Le Seed Industry, a company operating in the seed industry, which is a strategic and foundational sector for national food security and agricultural development [1][3][4]. Key Financial Performance - In 2024, Qiu Le Seed Industry achieved a revenue of 391 million yuan and a net profit of 50.44 million yuan [1]. Strategic Planning and Innovation - The company plans to increase investment in breeding corn, wheat, and peanuts, focusing on high-yield and resilient varieties to meet diverse market demands [2]. - Qiu Le Seed Industry aims to explore advanced biotechnologies such as transgenic and gene editing to enhance its product offerings [2][10]. Market Expansion and Sales Strategy - The company intends to deepen its presence in markets like Huang'an and expand into Northeast, Northwest, and Southwest regions, optimizing its development layout and enhancing brand recognition [2]. - Qiu Le Seed Industry is exploring order-based agriculture to improve product coverage and sales channels [2]. Mergers and Acquisitions - The company is actively seeking mergers with other seed companies that share similar values and have strong R&D capabilities to enhance its competitive edge [2]. Industry Context and Challenges - The seed industry is currently undergoing a rapid development phase, with many companies restructuring or repositioning themselves due to market changes [6]. - Historical adjustment cycles in the industry have been noted, with significant changes occurring approximately every ten years [6]. Product Development and Collaborations - Qiu Le Seed Industry has introduced several new corn varieties, including Qiu Le 368, which is among the top ten promoted varieties in the country [8]. - Collaborations with various research institutions and universities are ongoing to develop new products, including transgenic varieties that are nearing market introduction [10]. Commitment to National Strategy - The company emphasizes its alignment with national agricultural strategies, aiming to ensure food security and promote the revitalization of the seed industry [3][5]. Conclusion and Investor Engagement - The conference concluded with an invitation for investor questions, indicating a commitment to transparency and engagement with stakeholders [11].

Core Viewpoint - The article discusses the rapid development and potential of the biomanufacturing industry, highlighting its role in the Fourth Industrial Revolution and the significant growth opportunities it presents in various sectors, particularly in China [3][4]. Industry Overview - Biomanufacturing is defined as an advanced production method centered on industrial biotechnology, utilizing biological resources and processes to produce target products at scale [5]. - The global biomanufacturing industry is projected to reach approximately $12,190 billion in 2024, with a year-on-year growth of 7.4%, and is expected to exceed $20 trillion by 2030, with a compound annual growth rate (CAGR) of 8.4% [9]. Market Dynamics - In China, the biomanufacturing industry is anticipated to reach a scale of 1.01 trillion yuan in 2024, growing by 15.4%, and is expected to surpass 2.5 trillion yuan by 2030, with a CAGR of 16.8% [9][10]. - The top three segments in China's biomanufacturing industry in 2024 will be biopharmaceuticals, biological food, and bio-chemical products, with biopharmaceuticals remaining the largest segment [10]. Technological Advancements - The industry is experiencing a shift from traditional resource reliance to technology-driven approaches, with significant improvements in biomass resource utilization and equipment efficiency [8]. - Innovations in biopharmaceuticals, such as the development of bispecific antibodies and ADC drugs, have seen an annual growth of 65% in product pipelines [8][12]. Application and Impact - In the medical field, biomanufacturing technologies like 3D printing are enabling personalized implants, achieving gross margins of 75% [9]. - In agriculture, microbial fertilizers have improved corn yields by 12% while reducing chemical fertilizer usage by 30% [9]. Future Trends - The article outlines several key trends, including the restructuring of industrial ecosystems, regional layout changes, deepening technological revolutions, product innovation iterations, and capital factor restructuring [17][18][19]. - The integration of AI and biotechnology is expected to enhance production efficiency and product quality, with significant implications for the industry [18]. Strategic Recommendations - Companies are encouraged to build a three-dimensional competitive system focusing on technology research and development, scene innovation, and ecosystem construction [20]. - Local governments should create a supportive industrial service matrix to foster the growth of the biomanufacturing sector [20].

Group 1 - The core viewpoint emphasizes the importance of basic research in driving scientific and technological progress, while highlighting the challenges faced by young researchers in this field [1] - Young researchers should focus on finding intersections between academic hotspots and practical issues, particularly in fields like artificial intelligence and healthcare [2] - The strategy of "cold spots within hot topics" can be beneficial, allowing researchers to explore under-explored areas within popular fields [2] Group 2 - A "dual-track" research model is recommended, where researchers can pursue both short-term projects with immediate outputs and long-term core issues [3] - Breaking down long-term goals into smaller, manageable objectives can help maintain progress and yield periodic results [3] - Establishing a personal academic label in a specific niche can enhance a researcher's reputation over time, even in the absence of immediate breakthroughs [3] Group 3 - Effective cross-disciplinary collaboration requires overcoming barriers such as disciplinary silos, communication challenges, and issues related to benefit distribution [4] - Creating a "common language" among collaborators is essential for smooth communication and understanding of different disciplines [4] - Focusing on specific interdisciplinary scientific problems rather than general discussions can lead to more productive collaborations [5]

Core Viewpoint - The recent failure of Organon's candidate drug OG-6219 in Phase II clinical trials highlights the challenges in developing effective treatments for endometriosis, a condition affecting approximately 190 million women globally, with significant implications for the company's innovation pipeline and the broader market for pain management in women’s health [1][2][9]. Group 1: Market Demand and Supply - Endometriosis is a high-prevalence disease that causes severe pelvic pain and can lead to infertility, affecting about 1 in 10 women of reproductive age [1]. - Despite the significant treatment demand, there is a scarcity of new drugs, primarily due to the unclear underlying mechanisms of the disease, which complicates research and development [2][4]. - The complexity of individual patient factors, such as hormonal levels and inflammation, further complicates the development of effective treatments, leading to a low conversion rate for new mechanism drugs [2][4]. Group 2: Challenges in Drug Development - Existing treatments, such as NSAIDs, provide temporary relief but do not address the root cause of endometriosis, creating a high barrier for new drugs to demonstrate superior efficacy [2][3]. - High costs and side effects associated with approved drugs, such as AbbVie’s Orilissa and Pfizer’s Myfembree, have limited market acceptance [3][4]. - The failure of Organon’s OG-6219, which was expected to be a breakthrough treatment, underscores the difficulties in drug development within this therapeutic area [7][8]. Group 3: Organon's Position - Organon, formed from Merck's spinoff, aimed to innovate in women's health through acquisitions, including the purchase of Forendo Pharma for $750 million, which included OG-6219 [6]. - The failure of OG-6219 has significantly impacted Organon's innovation pipeline, leaving it with limited options for future development in endometriosis treatment [7][8]. - Despite the setback, Organon has expressed intentions to explore new treatment options for endometriosis, although the high difficulty and long timelines in this field pose significant challenges [8][12]. Group 4: Future Outlook - While the failure of OG-6219 is disappointing, the potential for innovation in endometriosis treatment remains, with ongoing research into alternative pathways and new compounds [10][11]. - Current research efforts are primarily focused on traditional pathways, but there are emerging explorations into novel approaches, such as cannabinoid therapies and inflammation-targeting strategies [11]. - A significant shift in the treatment landscape may require breakthroughs in technology and a renewed commitment from the industry to address the unmet medical needs of millions of women suffering from endometriosis [12].